Red Arrow Therapeutics develops pH-sensing nanomedicine drug delivery technologies, including a lead program of IL-12-loaded nanopolymeric micelles. The company plans to use the recent financing to obtain key preclinical safety and efficacy data for that lead compound. Funding will also enable initiation of manufacturing in collaboration with external partners. The Seed extension boosts the company’s cumulative funding to nearly $5.5M, supplementing prior support from The University of Tokyo Edge Capital Partners, UC Berkeley’s SkyDeck accelerator, and non-dilutive sources. Red Arrow emerged from the University of Tokyo’s Cabral Lab in 2021 and focuses on multiple therapeutic areas such as oncology. Founders include Takuya Miyazaki, Horacio Cabral and Rika Tajima, and the company maintains an office in Tokyo.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2024